CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitr...
Phase 1
San Antonio, Texas, United States and 32 other locations
This study is to evaluate the safety and tolerability of RMC-9805 in adults with KRAS G12D-mutant solid tumors.
Phase 1
San Antonio, Texas, United States and 6 other locations
the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer...
Phase 1
San Antonio, Texas, United States and 5 other locations
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Phase 1
San Antonio, Texas, United States and 14 other locations
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of CO...
Phase 1
San Antonio, Texas, United States and 8 other locations
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemothe...
Phase 1, Phase 2
San Antonio, Texas, United States and 11 other locations
This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in combination with TNO155 in pat...
Phase 1, Phase 2
San Antonio, Texas, United States and 11 other locations
This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.
Phase 1
San Antonio, Texas, United States and 12 other locations
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody ta...
Phase 1
San Antonio, Texas, United States and 18 other locations
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal...
Phase 1, Phase 2
San Antonio, Texas, United States and 4 other locations
Clinical trials
Research sites
Resources
Legal